← All diseases Blood and bone marrow

Myelofibrosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the most rigorous evidence (43)Treatment guideline (6)Meta-analysis (5)Phase 3 study (19)Randomized trial (9)Systematic review (4)Clinical Trial (599)Review article (228)Early study (phase 1 or 2) (41)Case reports (176)Laboratory or animal research (16)Commentary or editorial (73)Retracted publication (1) Studies currently recruiting participants only (37)

Filter

Publications (1031)

• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression. (2019/10/10) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Autoimmune panmyelosis with myelofibrosis. (2019/10/10) ♡
• Myeloid sarcoma manifesting as generalized lymphadenopathy in a patient with myelofibrosis. (2019/10/04) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes: A Systematic Review and Meta-analysis. (2019/10/02) ♡
• Home enteral nutrition may prevent myelosuppression of patients with nasopharyngeal carcinoma treated by concurrent chemoradiotherapy. (2019/10/01) ♡
• Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients. (2019/10/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Fedratinib: First Approval. (2019/10/01) ♡
• Gene Polymorphism of Xenobiotic Biotransformation Enzymes in Patients with Classical Ph-Negative Myeloproliferative Neoplasms. (2019/10/01) ♡
• Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes. (2019/09/30) ♡
• Conjugated polymers optically regulate the fate of endothelial colony-forming cells. (2019/09/27) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Standard care and investigational drugs in the treatment of myelofibrosis. (2019/09/26) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology. (2019/09/19) ♡
• A rare cause of acute coronary syndromes in young adults - myeloproliferative neoplasms: A case series. (2019/09/01) ♡
• Treatment outcome of Philadelphia chromosome negative myeloproliferative neoplasms: experience of a single developing country's hematology-oncology centre. (2019/09/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms. (2019/08/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Fatal case of TAFRO syndrome associated with over-immunosuppression: a case report and review of the literature. (2019/08/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Hodgkin lymphoma with co-existing extramedullary haematopoiesis in a Thalasaemia Major patient: Killing two birds with one stone using PET-CT. (2019/07/01) ♡
• AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor Cells. (2019/06/04) ♡
• Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis. (2019/06/01) ♡
• Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. (2019/05/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Mutations and prognosis in myeloproliferative neoplasms. (2019/05/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. (2019/05/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Sphingolipid dysregulation due to lack of functional KDSR impairs proplatelet formation causing thrombocytopenia. (2019/05/01) ♡
• Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms. (2019/05/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A confusing 'white cell count': Circulating micromegakaryocytes in post-thrombocythemia myelofibrosis. (2019/05/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. (2019/05/01) ♡
• Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis. (2019/04/11) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. (2019/04/01) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. (2019/04/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Osteoradionecrosis of the sternoclavicular joint after laryngopharyngeal radiation. (2019/04/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis. (2019/04/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. (2019/04/01) ♡
• Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. (2019/04/01) ♡
• Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. (2019/04/01) ♡
• Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms. (2019/04/01) ♡
• Erratum to correct 'How we approach: Severe congenital neutropenia and myelofibrosis due to mutations in VPS45'. (2019/04/01) ♡
• Chromosome 12 Rearrangement in an Adolescent with Primary Myelofibrosis. (2019/04/01) ♡
• Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis. (2019/03/01) ♡
• Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. (2019/03/01) ♡
• Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis. (2019/03/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Singular case of osteolytic lesions revealing transformation of myeloproliferative syndrome to acute leukemia. (2019/03/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. The JAK2 46/1 (GGCC) MPN-predisposing haplotype: A risky haplotype, after all. (2019/03/01) ♡
• The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis. (2019/03/01) ♡
• 20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients. (2019/03/01) ♡
• WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis. (2019/03/01) ♡
• Outcome of Childhood Acute Megakaryoblastic Leukemia: Children's Cancer Hospital Egypt 57357 Experience. (2019/03/01) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice. (2019/03/01) ♡
• Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2(V617F) against myeloproliferative neoplasms. (2019/02/04) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Treating early-stage myelofibrosis. (2019/02/01) ♡
• Adolescent and Young Adult Chronic Myeloid Leukemia in Real-World Settings: Experience from a Tertiary Care Institute in Northern India. (2019/02/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.